{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:53:11Z","timestamp":1789854791880,"version":"4.0.1"},"reference-count":11,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1136\/archdischild-2017-312941","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T01:00:33Z","timestamp":1502326833000},"page":"958-962","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study"],"prefix":"10.1136","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8298-977X","authenticated-orcid":false,"given":"Viveka","family":"Nainani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ushma","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,9]]},"reference":[{"key":"key-10.1136\/archdischild-2017-312941-1","unstructured":"McKee S . Real world data back efficacy of GSK\u2019s Bexsero. 2016 http:\/\/www.pharmatimes.com\/news\/real_world_data_back_efficacy_of_gsks_bexsero_1122744"},{"key":"key-10.1136\/archdischild-2017-312941-2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"key-10.1136\/archdischild-2017-312941-3","unstructured":"National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management. 2013 https:\/\/www.nice.org.uk\/guidance\/cg160\/chapter\/1-recommendations"},{"key":"key-10.1136\/archdischild-2017-312941-4","unstructured":"Public Health England. Using Paracetamol to prevent and treat fever after MenB vaccination: national Health Service. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/483408\/9413-paracetamol-menB-2page-A4-08-web.pdf"},{"key":"key-10.1136\/archdischild-2017-312941-5","unstructured":"Public Health England. The UK immunisation schedule 2015. 2015 https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/400554\/2902222_Green_Book_Chapter_11_v2_4.pdf"},{"key":"key-10.1136\/archdischild-2017-312941-6","volume-title":"Global manual on surveillance of adverse events following immunization","author":"World Health Organisation","year":"2014"},{"key":"key-10.1136\/archdischild-2017-312941-7","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2017-312941-8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(09)61208-3","article-title":"Effect of prophylactic Paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials","volume":"374","author":"Prymula","year":"2009","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2017-312941-9","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.vaccine.2017.02.035","article-title":"A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations","volume":"35","author":"Wysocki","year":"2017","journal-title":"Vaccine"},{"key":"key-10.1136\/archdischild-2017-312941-10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.4161\/hv.28666","article-title":"A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)","volume":"10","author":"Prymula","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.1136\/archdischild-2017-312941-11","article-title":"Infant fever trends following the launch of the meningococcal B vaccine in the UK","volume":"9","author":"Harcourt","year":"2017","journal-title":"J Public Health Inform"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2017-312941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T11:06:55Z","timestamp":1601118415000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2017-312941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,9]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,9,20]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/archdischild-2017-312941"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2017-312941","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,9]]}}}